AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00524303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: 1250 mg oral daily dose in arm 2, 750 mg oral daily dose for FEC cycles and then 1000 mg oral daily dose during the Paclitaxel cycles in arm 3
Study NCT00991900 — intervention group
Intervention type: DEVICE
Intervention: Measurement of oxygen saturation of retinal vessels with optical reflectometer
Description: 5 repeated measurements on both study days
Study NCT00833859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GTX (gemcitabine, docetaxel and capecitabine)
Description: GTX: 21 day cycle x 2 Gemcitabine 750mg/m2 on days 4 and 11 Taxotere® (docetaxel) 30 mg/m2 on days 4 and 11 Xeloda® (capecitabine) 750 mg/m2 on days 1-14
Study NCT00833859 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiation therapy
Description: stereotactic body radiation therapy (SBRT) 25
Study NCT00499915 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Secondhand Smoke Reduction and Smoking Cessation Counseling
Description: A secondhand smoke reduction program, including smoking cessation counseling (if appropriate), and feedback about the children's cotinine levels will be implemented using principles of Motivational Interviewing.
Study NCT00499915 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Asthma Education
Description: Asthma education will be provided at NICU discharge.
Study NCT00499915 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Asthma Education
Description: Asthma education will be provided at NICU discharge.
Study NCT06656455 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sevoflurane via LMA
Description: In Group S, co-induction is used whereby the patient continues to receive 8% sevoflurane through the facemask followed after IV insertion by propofol 2mg/kg and fentanyl 1mic/kg administration. Thirty seconds afterwards, an age-appropriate LMA will be inserted. Sevoflurane is maintained initially at a concentration of 2%. The ventilation at first is assisted manually until the child starts breathing. If movement requires interruption of the exam, a bolus of propofol 1mg/kg is given and sevoflurane is increased by 1% until a maximal sevoflurane concentration of 4%. If apnea related to the depth of anesthesia occurs more than 10 sec or the saturation drops below 94%, sevoflurane will be turned off until the proper airway intervention is taken to achieve saturation above 95% and sevoflurane will be resumed at a concentration decreased by 1%.
Study NCT03667729 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: progressive muscle relaxation
Description: intervention group: The experimental group received muscle relaxation training once a week for 3 consecutive months. The results were measured and followed up after 3 months.
Study NCT03972683 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Handgrip Exercise Training
Description: Signaling mechanisms that regulate blood flow will be studied before and after 7 weeks of handgrip exercise training with the non-dominant forearm. Training sessions will consist of 30 min of rhythmic contractions using a handgrip exercise device, and participants will complete four training sessions per week.
Study NCT03972683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylcholine
Description: Vasodilatory sensitivity to acetylcholine will be assessed in dose-response fashion as a standard test of vascular function. Doses of 0.5, 1.5, and 15 μg/dl forearm volume/min will be infused via a brachial artery catheter for 4 min per dose.
Study NCT03972683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adenosine Triphosphate
Description: Vasodilatory sensitivity to adenosine triphosphate will be assessed during infusion of a dose of 10 μg/dl forearm volume/min administered via a brachial artery catheter over a total of 4 min.
Study NCT03972683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine
Description: Atropine will be used to inhibit muscarinic acetylcholine receptors in order to determine the contribution of acetylcholine to vasodilation during exercise. An initial dose of 0.2 mg will be infused via a brachial artery catheter over 3 min, then a maintenance dose of 0.067 mg will be infused over 1 min prior to each of 5 subsequent experimental trials.
Study NCT03972683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: Vasoconstriction to phenylephrine will be used to assess sensitivity to alpha 1 adrenergic stimulation. Phenylephrine will be infused via a brachial artery catheter at 0.125 or 0.25 μg/dl forearm volume/min (18-35 and 60-85 age groups, respectively), adjusted according to forearm blood flow, for a total of 16 min.
Study NCT03972683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Nitroprusside
Description: Sodium nitroprusside will be infused via a brachial artery catheter as a control vasodilator to elevate resting forearm blood flow to a level similar to that during exercise. The dose will be adjusted to match forearm blood flow to a similar level as during handgrip exercise, with an anticipated average dose of 1 μg/dl forearm volume/min. The dose will be infused for a total of 14 min.
Study NCT02281994 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pulsed Electromagnetic Feld (PEMF) Orthofix Cervical-Stim Model 2205OD
Description: Active devices emit PEMF signal; control devices do not emit PEMF signal.
Study NCT02281994 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Pulsed Electromagnetic Feld (PEMF) Orthofix Cervical-Stim Model 2205OD
Description: Active devices emit PEMF signal; control devices do not emit PEMF signal.
Study NCT02532244 — intervention group
Intervention type: OTHER
Intervention: sample collection
Description: collection of blood
Study NCT02465060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adavosertib
Description: Given PO
Study NCT02465060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: Given PO
Study NCT02465060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib Dimaleate
Description: Given PO
Study NCT02465060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: Given PO
Study NCT02465060 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy
Study NCT02465060 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT02465060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capivasertib
Description: Given PO
Study NCT02465060 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo computed tomography (CT)
Study NCT02465060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib
Description: Given IV
Study NCT02465060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib Hydrochloride
Description: Given IV
Study NCT02465060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: Given PO
Study NCT02465060 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cytology Specimen Collection Procedure
Description: Optional correlative studies
Study NCT02830087 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tourniquet Cuff Pressure
Description: Tourniquet cuff pressure is how hard the tourniquet cuff, which is placed around the patient's thigh, presses on the thigh in order to cut off blood supply to the lower leg during total knee surgery.
Study NCT00850044 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABT-450
Description: capsules,QD, one dose, see Arm Descriptions for more information
Study NCT05675085 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Personalized screening protocol
Description: At the first screening round (recruitment) all participating women had the same tests;~* Two-view tomosynthesis of both breasts~* Calculation of volumetric breast density (VBD)~* Calculation of lifetime risk (LTR) using the Tyrer-Cuzick model~At subsequent rounds:~1. Women with non-dense breasts and low breast cancer risk are re-screened only with DBT every 2 years;~2. Women with dense breasts and low breast cancer risk are re-screened with DBT+US every 2 years;~3. Women with non-dense breasts and intermediate breast cancer risk are re-screened only with DBT every year;~4. Women with dense breasts and intermediate breast cancer risk are re-screened with DBT+US every year;~5. Women at high risk of breast cancer associated with a family history of breast cancer (w/wo hereditary factors) undergo DBT and MRI every year.
Study NCT03927716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB206 12%
Description: Topically once daily
Study NCT03927716 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Topically once daily
Study NCT02633657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HORIZANT 300 mg
Description: HORIZANT 300 mg once daily
Study NCT04002557 — intervention group
Intervention type: OTHER
Intervention: Interview-Questionnaire
Description: Questionnaire
Study NCT00443326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 714
Description: Dosing Regimen is 6 Doses over 3 Months
Study NCT02539693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine 75 µg/mL in sacrococcygeal block
Description: Sacrococcygeal block will be performed using 75 µg/mL clonidine in the anesthetic mixture
Study NCT02539693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine 150 µg/mL in sacrococcygeal block
Description: Sacrococcygeal block will be performed using 150 µg/mL clonidine in the anesthetic mixture
Study NCT02539693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: 3 ml lidocaine 1% is injected at each block site
Study NCT02539693 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pilonidal sinus
Description: Removal of pilonidal sinus
Study NCT02679092 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: 400 mcg buccal 60-90 minutes prior to procedure
Study NCT02679092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: 400 mcg buccal 60-90 minutes prior to procedure
Study NCT02679092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: 200 mg PO on the day prior to D\&E
Study NCT02679092 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hygroscopic cervical dilators
Description: osmotic cervical dilators inserted through the internal os
Study NCT00290238 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vertis Percutaneous Neuromodulation Therapy (PNT)
Description: * Ten PNT sessions in eleven weeks~* On average, one PNT session per week~* Ten lumbar Safeguide electrodes (three centimeters in length) deployed per lumbar montage~* Forty-five minutes of electrical stimulation for each session~* Electrical stimulation parameters:~  * Continuous 50 Hz current~ * Charge-balanced, biphasic (each phase is 200 microsec), rectangular waveform~ * Intensity to subject's tolerance for ten minutes then increased to a mildly uncomfortable level
Study NCT00850044 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ritonavir
Description: capsules, QD, one dose, escalating doses, see Arm Descriptions for more information
Study NCT00290238 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS)
Description: * Ten TENS sessions in eleven weeks~* On average, one TENS session per week~* Four 2-inch (5.1 centimeters) diameter pads applied per TENS lumbar montage~* Forty-five minutes of electrical stimulation for each session~* Electrical stimulation parameters:~  * Current at 2 Hz-low frequency~ * Pulse trains delivered as asymmetric, biphasic, square waveform current, with pulse width lasting 20 microsec~ * Intensity titrated according to subject's sensory threshold~ * To maintain blinding, the treating physician or clinician will check on the subject after 10 minutes and dial the channels down just prior to the point of turning off the device.
Study NCT04419974 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Molecular Diagnosis
Description: Double-blind molecular diagnosis for the SCA3/MJD mutation.
Study NCT04419974 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical Scales - Baseline
Description: SARA, NESSCA, ICARS, INAS, SCAFI, CCFS will be applied on baseline.
Study NCT02053454 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: patisiran (ALN-TTR02)
Description: Ascending doses administered by intravenous (IV) infusion
Study NCT02053454 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sterile Normal Saline (0.9% NaCl)
Description: Calculated volume to match active comparator
Study NCT03016650 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Patients receive 100 mL of physiologic saline with 1 g IV paracetamol 30 minutes before the end of the operation and postoperatively 6, 12 and 18 hours after PCNL
Study NCT03016650 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Patients receive 100 mL of physiologic saline with 800 mg IV ibuprofen 30 minutes before the end of the operation and postoperatively 6, 12 and 18 hours after PCNL
Study NCT03447353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xanax 1Mg Tablet
Description: Single dose on two of four visits, one in conjunction with 1 tab of 10mg/325mg Norco
Study NCT04419974 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Draw - Baseline
Description: Blood collection on baseline for evaluation of~* Candidate genes expression~* Serum proteins~* Lymphocytic proteins
Study NCT04419974 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Quality of Life Assessment - Baseline
Description: Participants fill out 2 self-reported quality of life questionnaires.
Study NCT04419974 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical Scales - Follow-up 12 months
Description: SARA, NESSCA, ICARS, INAS, SCAFI, CCFS will be applied 12 months after baseline for prospective evaluation.
Study NCT00850044 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo for ABT-450
Description: capsules, QD, one dose
Study NCT04419974 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Draw - Follow-up 12 months
Description: Blood collection 12 months after baseline for prospective evaluation of~* Candidate genes expression~* Serum proteins~* Lymphocytic proteins
Study NCT00850044 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for ritonavir
Description: capsules, QD, one dose
Study NCT02208882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986120
Study NCT04419974 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Quality of Life Assessment - Follow-up 12 months
Description: Participants fill out 2 self-reported quality of life questionnaires for prospective evaluation.
Study NCT02208882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT04419974 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical Scales - Follow-up 24 months
Description: SARA, NESSCA, ICARS, INAS, SCAFI, CCFS will be applied 24 months after baseline for prospective evaluation.
Study NCT06656455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol with oxygen via simple mask
Description: In group P, the sevoflurane will be discontinued, and propofol 1 mg/kg and fentanyl 1µg/kg will be administered IV. Propofol pump is maintained initially at a rate of 200mic/kg/min. with oxygen at 3 liters/min via facemask.~If movement requires interruption of the exam, a bolus of propofol 1mglkg is given and the infusion rate is increased by 20mic/kg/min up to a maximal rate of 350mic/kg/min. The total number of boluses needed will be recorded as the need for additional sedation. If apnea related to the depth of anesthesia occurs more than 10 sec or the saturation drops below 94%, the infusion pump will be stopped until the proper airway intervention is taken to achieve saturation above 95% with spontaneous breathing. Afterwards, the propofol pump will be resumed at a rate decreased by 20mic/kg/min.
Study NCT04419974 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Draw - Follow-up 24 months
Description: Blood collection 24 months after baseline for prospective evaluation of~* Candidate genes expression~* Serum proteins~* Lymphocytic proteins
Study NCT04419974 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Quality of Life Assessment - Follow-up 24 months
Description: Participants fill out 2 self-reported quality of life questionnaires for prospective evaluation.
Study NCT03447353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norco 10Mg-325Mg Tablet
Description: Single dose on two of the four study visits, one in conjunction with 1mg alprazolam
Study NCT04645056 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stretching and Mobility exercises for neck and shoulder
Description: 9 specific stretching and mobility exercises performed 3 times every day the first 4 weeks after surgery.
Study NCT01426646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: S-1 was administered at 40mg/m2 orally twice daily (days 1-28) every 42 days. Patients received a maximum of eight cycles.
Study NCT03447353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Tablet
Description: Single dose on two of the four study visits, double dose on one of the four study visits
Study NCT01426646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1 plus cisplatin
Description: S-1 plus cisplatin every 3 weeks, a total of eight cycles~* S-1: 40mg/m2 orally twice daily (days 1-14)~* Cisplatin: 60mg/m2 IV on day 1
Study NCT03842800 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: MRI
Description: Patients and volunteers will receive an MRI.
Study NCT03842800 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI
Description: Patients and volunteers will receive an MRI.
Study NCT03842800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine will be administered to a subset of healthy controls that agree to receive the drug as part of receiving an MRI.
Study NCT02851524 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: posturography
Study NCT02208882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Study NCT02811289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirbetriq (Mirabegron)
Description: 50mg of Mirabegron will be administered orally at time 0 in protocol A.
Study NCT02811289 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cold exposure
Description: Acute cold exposure protocol using a water-conditioned cooling suit will be applied from time 120 to 300 min in protocol B
Study NCT02811289 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: injection of 18FDG
Description: I.v. injection of 18-fluorodeoxyglucose (18FDG) will be performed at time 270 min, followed by 30 min dynamic PET/CT scanning
Study NCT02811289 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: injection of 18FDG
Description: I.v. injection of 18-fluorodeoxyglucose (18FDG) will be performed at time 270 min, followed by 30 min dynamic PET/CT scanning
Study NCT02811289 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: injection of 11C-acetate
Description: i.v. injection of 11C-acetate will be performed, followed by 20 min dynamic PET/CT scanning
Study NCT02811289 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: injection of 11C-acetate
Description: i.v. injection of 11C-acetate will be performed, followed by 20 min dynamic PET/CT scanning
Study NCT02811289 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: [3-3H]-glucose
Description: i.v. administration of 1.5 uCi/min of \[3-3H\]-glucose
Study NCT02811289 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [3-3H]-glucose
Description: i.v. administration of 1.5 uCi/min of \[3-3H\]-glucose
Study NCT02811289 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: [U-13C]-palmitate
Description: i.v. administration of 0.08 umol/kg/min of \[U-13C\]-palmitate
Study NCT02811289 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: [U-13C]-palmitate
Description: i.v. administration of 0.08 umol/kg/min of \[U-13C\]-palmitate
Study NCT02811289 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 2H-Glycerol
Description: i.v. administration of 0.05 µmol/kg/min of 2H-glycerol
Study NCT02811289 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2H-Glycerol
Description: i.v. administration of 0.05 µmol/kg/min of 2H-glycerol
Study NCT01684826 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Angiographic run with new algorithm and low dose (50% dose)
Description: Angiographic run with new algorithm and low dose (50% lower dose compared to Xper)
Study NCT01684826 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Angiographic run with predecessor algorithm and dose (100%)
Description: Angiographic run with predecessor algorithm and dose (100% dose)